Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

York Teaching Hospital Signs Up BD FocalPoint™

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
Fifth NHS cytology centre adopts Source BioScience’s automated screening technology.

Source BioScience has announced that, following a competitive tender process, York Teaching Hospital NHS Foundation Trust (‘York’) has renewed its contract for liquid based cytology (‘LBC’).

York has also committed to implementing Source BioScience’s automated cervical cancer screening BD FocalPoint™ technology.

The agreement is worth a total of £1.3 million over three years and was commenced on 1 April 2013.

Source BioScience provides customers with a unique and complete solution for cervical cancer screening, including HPV testing, from sample collection, processing, imaging and diagnostic testing.

The newest development in the screening process is BD FocalPoint™, the only automated technology for cervical cancer screening approved for use by the NHS, which is distributed in the UK by Source BioScience alone.

The BD FocalPoint™ technology is able to analyze and identify up to 25% of screening samples that can be reported as “No Further Review” (NFR) requiring no primary manual examination.

With over 3.9 million tests being undertaken across England and Wales during 2011-2012, the BD FocalPoint™ technology represents a significant reduction in laboratory workload and the need for additional staffing and outsourcing.

York Teaching Hospital is the fifth NHS cytology centre in England and Wales to adopt Source BioScience’s BD FocalPoint™ and the 7th platform to be placed within the NHS. This contract increases the aggregate value of the automated imaging business to Source BioScience to £0.6 million per annum over the next three years.

Trevor Hair, Head Biomedical Scientist for Cytology at York, said: “We’re delighted to have secured this contract on behalf of the Trust. In taking on additional cervical screening work from Hull and East Riding, our workload will increase from around 54,000 to 90,000 samples a year. The contract will make York laboratory the single cervical cytology screening provider for North and East Yorkshire and mean that all women who require a cervical screening test will now be able to have their samples examined at a single laboratory that will utilize the latest technology available in the UK.”

Dr Nick Ash, CEO at Source BioScience, commented: “Since the NHS published its implementation guidelines in July 2011, there has been significant interest from NHS Trusts in the BD FocalPoint™ technology. The renewal of the York contract and the adoption of the technology by another NHS Trust, demonstrates the determination to provide better timeliness and efficiencies for cervical cancer screening. This technology is an important growth driver for our business and we aim to win more contracts during 2013.”

During 2012, over two million women had their cervical cancer screening test undertaken using the technology provided by Source BioScience, which represents over 50% of all testing in England and Wales.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Source BioScience Launches New Overnight Service for DNA Sequencing
Overnight service offers free sample collection and rapid delivery of results in Scotland.
Monday, June 17, 2013
Source BioScience Announces Acquisition of Inverclyde Biologicals Limited
Acquisition of the entire issued share capital of Inverclyde for total consideration of £1.6 million.
Tuesday, April 30, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!